TY  - JOUR
A1  - Lauth, Jakob
A1  - Hoelderich, W.
A1  - Wagenblast, G.
T1  - Crystalline zeolites containing indigo dyes
JF  - Zeolites. 15 (1995), H. 1
Y1  - 1995
SN  - 0144-2449
SP  - 86
ER  - 
TY  - JOUR
A1  - Biselli, Manfred
A1  - Noll, Thomas
A1  - Jelinek, Nanni
A1  - Schmidt, Sebastian
T1  - Cultivation of Hematopoietic Stem and Progenitor Cells: biochemical Engineering Aspects / Thomas Noll, Nanni Jelinek, Sebastian Schmidt, Manfred Biselli und Christian Wandrey
JF  - Tools and Applications of Biochemical Engineering Science
Y1  - 2002
SN  - 3-540-42250-1
N1  - Advances in Biochemical Engineering/Biotechnology. 74
SP  - 111
EP  - 128
PB  - Springer
CY  - Berlin
ER  - 
TY  - JOUR
A1  - Biselli, Manfred
A1  - Hilbert, U.
A1  - Noll, T.
T1  - Cultivation of Human HCMV Specific Lymphocytes – An Example for  Adoptive Immunotherapy / Hilbert, U. ; Biselli, M. ; Noll, T.
JF  - Animal cell technology : from target to market ; Tylösand, Sweden, June 10 - 14, 2001 / ed. by E. Lindner-Olsson ...
Y1  - 2001
SN  - 1-4020-0264-5
N1  - Proceedings of the ... ESACT meeting ; 17
SP  - 558
EP  - 561
PB  - Kluwer
CY  - Dordrecht
ER  - 
TY  - JOUR
A1  - Schnitzler, Thomas
T1  - Cultivation of hybridoma cell line CF-10H5 (DSMZ ACC477)
JF  - Application notes / Sartorius stedim biotech
Y1  - 2009
SP  - 1
EP  - 4
ER  - 
TY  - BOOK
A1  - Lauth, Jakob
A1  - Dingerdissen, Uwe
A1  - Steuerle, Ulrich
T1  - Cup catalyst and process for producing aziridines : [Internationale Pantentanmeldung WO9633018] ; Veröffentlichungsdatum: 1996-10-24 / Anmelder: BASF AG ; Dingerdissen, Uwe ; Lauth, Guenther ; Steuerle, Ulrich. Erfinder: Dingerdissen, Uwe ; Lauth, Guenther ; Steuerle, Ulrich
Y1  - 1996
PB  - [Weltorganisation für geistiges Eigentum]
CY  - [Genf]
ER  - 
TY  - JOUR
A1  - Henderson, Colin J.
A1  - Mclaughlin, Lesley A.
A1  - Scheer, Nico
A1  - Stanley, Lesley A.
A1  - Wolf, C. Roland
T1  - Cytochrome b5 Is a Major Determinant of Human Cytochrome P450 CYP2D6 and CYP3A4 Activity In Vivo s
JF  - Molecular Pharmacology
Y1  - 2015
U6  - http://dx.doi.org/10.1124/mol.114.097394
SN  - 1521-0111
VL  - 87
IS  - 4
SP  - 733
EP  - 739
PB  - ASPET
CY  - Bethesda
ER  - 
TY  - JOUR
A1  - Feuerriegel, Uwe
A1  - Klose, W.
A1  - Sloboshanin, S.
A1  - Goebel, H. [u.a.]
T1  - Deactivation of a palladium-supported alumina catalyst by hydrogen sulfide during the oxidation of methane
JF  - Langmuir: the ACS journal of surfaces and colloids. 10 (1994), H. 10
Y1  - 1994
SN  - 0743-74363
SP  - 3567
EP  - 3570
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Kapelyukh, Yury
A1  - Rode, Anja
A1  - Oswald, Stefan
A1  - Busch, Diana
A1  - Mclaughlin, Lesley A.
A1  - Lin, De
A1  - Henderson, Colin J.
A1  - Wolf, C. Roland
T1  - Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model
JF  - Drug Metabolism and Disposition
Y1  - 2015
U6  - http://dx.doi.org/10.1124/dmd.115.065656
SN  - 1521-009x
VL  - 43
IS  - 11
SP  - 1679
EP  - 1690
PB  - ASPET
CY  - Bethesda
ER  - 
TY  - JOUR
A1  - Kapelyukh, Yury
A1  - Henderson, Colin James
A1  - Scheer, Nico
A1  - Rode, Anja
A1  - Wolf, Charles Roland
T1  - Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 KO mice
JF  - Drug Metabolism and Disposition
Y1  - 2019
U6  - http://dx.doi.org/10.1124/dmd.119.087718
IS  - Early view
ER  - 
TY  - JOUR
A1  - Scheer, Nico
A1  - Mclaughlin, Lesley A.
A1  - Rode, Anja
A1  - MacLeod, Alastair Kenneth
A1  - Henderson, Colin J.
A1  - Wolf, Roland C.
T1  - Deletion of thirty murine cytochrome P450 genes results in viable mice with compromised drug metabolism
JF  - Drug Metabolism and Disposition
N2  - In humans, 75% of all drugs are metabolized by the cytochrome P450-dependent monooxygenase system. Enzymes encoded by the CYP2C, CYP2D, and CYP3A gene clusters account for ∼80% of this activity. There are profound species differences in the multiplicity of cytochrome P450 enzymes, and the use of mouse models to predict pathways of drug metabolism is further complicated by overlapping substrate specificity between enzymes from different gene families. To establish the role of the hepatic and extrahepatic P450 system in drug and foreign chemical disposition, drug efficacy, and toxicity, we created a unique mouse model in which 30 cytochrome P450 genes from the Cyp2c, Cyp2d, and Cyp3a gene clusters have been deleted. Remarkably, despite a wide range of putative important endogenous functions, Cyp2c/2d/3a KO mice were viable and fertile, demonstrating that these genes have evolved primarily as detoxification enzymes. Although there was no overt phenotype, detailed examination showed Cyp2c/2d/3a KO mice had a smaller body size (15%) and larger livers (20%). Changes in hepatic morphology and a decreased blood glucose (30%) were also noted. A five-drug cocktail of cytochrome P450 isozyme probe substrates were used to evaluate changes in drug pharmacokinetics; marked changes were observed in either the pharmacokinetics or metabolites formed from Cyp2c, Cyp2d, and Cyp3a substrates, whereas the metabolism of the Cyp1a substrate caffeine was unchanged. Thus, Cyp2c/2d/3a KO mice provide a powerful model to study the in vivo role of the P450 system in drug metabolism and efficacy, as well as in chemical toxicity.
Y1  - 2014
U6  - http://dx.doi.org/10.1124/dmd.114.057885
SN  - 1521-009X
VL  - 42
IS  - 6
SP  - 1022
EP  - 1030
PB  - ASPET
CY  - Bethesda, Md.
ER  -